A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and
clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST.
The study consists of two parts: dose escalation (phase I) and dose expansion (phase II).